Effectiveness of using risk communication to help smokers with cancer quit smoking: A randomized controlled trial.

Authors

Ho Cheung William LI Li

William Ho Cheung Li

The Chinese University of Hong Kong, Sha Tin, Hong Kong

William Ho Cheung Li , David Chi Leung Lam , Kit Man Sin , Eliza Lai Yi Wong , Carlos K H Wong , Herbert H. Loong , Kai Yeung Cheung , Wei Xia , Peige Song , Joyce Oi Kwan Chung

Organizations

The Chinese University of Hong Kong, Sha Tin, Hong Kong, The University of Hong Kong, Hong Kong, Hong Kong, Tuen Mun Hospital, Hong Kong, China, The Chinese University of Hong Kong, Hong Kong, China, The University of Hong Kong, Hong Kong, China, The Chinese University of Hong Kong, Hong Kong, Hong Kong, United Christian Hospital, Hong Kong, China, Sun Yat-Sen University, Guangdong, China, Zhejiang University, Hangzhou, China, The Hong Kong Polytechnic University, Hong Kong, Hong Kong

Research Funding

Food and Health Bureau, Hong Kong Government

Background: Despite evidence that patients living with cancer who continue to smoke after diagnosis are at a higher risk for all-cause mortality and reduced treatment efficacy, many cancer patients continue to smoke. This study aimed to examine the effectiveness of using a brief risk communication approach to help smokers with cancer quit smoking. Methods: A randomized controlled trial was conducted on 528 patients who continued to smoke and were follow-up at five out-patient clinics in Hong Kong. A total of 268 subjects were randomly assigned to the intervention group that received health warnings on smoking, and 260 subjects were randomly assigned to the control group that received usual care. All subjects had follow-up telephone calls at 1week, 1 month, 3 months, 6 months and 12 months to assess smoking status. Results: The biochemically validated quit rate at the 6-month follow-up was higher in the intervention group than in the control group (5.2% vs 3.8%; OR 1.38, 95% CI 0.60–3.16). The rate of at least 50% self-reported reduction of smoking at 6 months, was higher in the intervention group than in the control group (16.8% vs 12.3%; OR 1.43, 95% CI 0.88–2.35).The results showed that many smokers diagnosed with cancer believed that it was too late to quit smoking. Many participants claimed that overcoming cigarette cravings was extremely difficult, and therefore felt that the barriers to quitting outweighed the perceived benefits. Conclusions: It is crucial to proactively implement novel and effective smoking cessation interventions for smokers with cancer. Importantly, it will help to improve the physical well-being and health-related quality of life of smokers with cancer and protect the public, especially vulnerable groups such as women and children, from exposure to second-hand smoke. This will ultimately save more lives, protect the environment, and boost sustainable development. Clinical trial information: NCT01685723.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Rapid Oral Abstract Session

Session Title

Rapid Oral Abstract Session C: Real-World Evidence and Artificial Intelligence/Health Tech

Track

Gastrointestinal Cancer,Hematologic Malignancies,Healthtech Innovations,Thoracic Cancers

Sub Track

Other Technology and Innovations

Clinical Trial Registration Number

NCT01685723

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 158)

DOI

10.1200/JCO.2024.42.23_suppl.158

Abstract #

158

Abstract Disclosures

Similar Abstracts

First Author: Elyse R. Park

Abstract

2022 ASCO Annual Meeting

Smoking cessation after cancer diagnosis: Relationships matter.

First Author: Melissa Francoise Neumann

Abstract

2024 ASCO Quality Care Symposium

Call to quit: Results of a remote, longitudinal tobacco cessation program.

First Author: Rebekah Kaufman

Abstract

2022 ASCO Annual Meeting

Smoking cessation counseling in patients with active malignancy.

First Author: Zachary M Avigan